Benzinga · Jul 30, 2026
GlucoTrack (GCTK) Stock Surges Over 70% After Hours: Why is it Moving?
GlucoTrack shares surged 70.25% after hours as investors reacted to its simplified single-injection strategy for LT-100 development.
GC
NASDAQ · GCTK
GlucoTrack, Inc.
Healthcare · Medical - Instruments & Supplies
$3.23
Up+$0.09 (+2.87%)
Updated Sep 11, 2026, 3:03 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.34M
- P/E ratio
- -0.66
- Dividend yield
- 0.00%
- 52-week range
- $0.25 – $5.25
- Volume
- 17.7K
- Avg. volume
- 1.24M
Price performance
GCTK price history
1M range · 0 trading sessions · Daily adjusted prices
GCTK does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest GCTK news
The latest Smart Investors Daily articles mentioning GCTK.
Stock researchCompany · Overview
GCTK research
Overview
Company profile and research snapshot.
Company profile
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Jul 29, 2026
GlucoTrack's Subsidiary, Lōkahi Therapeutics, Advances LT-100 Development Strategy Toward Single-Injection Administration; FDA Type C Meeting and Nonclinical Study Advance Strategy To Transition LT-100 From 15 Injections To One
Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced progress in its LT-100 development strategy focused on evaluating whether a historical administration approach
Benzinga · Jul 28, 2026
Glucotrack Has Been Granted U.S. Patent Number 12,129,085 Titled "Methods and systems for continuously monitoring the glucose level of a patient".
https://ppubs.uspto.gov/pubwebapp/external.html?q=(12690787).pnhttps://x.com/PatentGrants/status/2082194682885587390
Benzinga · Jul 21, 2026
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's regular session. The company's market cap stands at $36.8 million. Wellgistics Health (NASDAQ:WGRX) shares increased
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
